HROW

#2210
Harrow, Inc. - Common Stock
38.5 3 USD
-0.01%
Market Price
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
38.13
38.58
Year Range
28.54
54.85
Daily Change
-1.33%
Monthly Change
-1.58%
6 month change
-1.23%
Year Change
-1.21%
Previous Close
39.0 5
Open
38.4 5
Low
38.1 3
High
38.5 8
Volume
55
Open full chart

Financials

Overview Statement Statistics Documents

2026

Current report, Q3 FY2026
HARROW, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
HARROW, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
HARROW, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
HARROW, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
HARROW, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
HARROW, INC. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
HARROW, INC. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
HARROW, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
HARROW, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
HARROW, INC. current report, Q1 FY2026
8-K

HARROW, INC. current report, 24 May 2019

Full document

Harrow Health, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Harrow Health, Inc. (HROW) on May 29, 2019, reporting events occurring on May 24, 2019. The filing details a material amendment to the Company's existing term loan and security agreement with SWK Funding LLC.

Key Financial Metrics and Debt Structure

The filing focuses on debt restructuring rather than operational financial performance. Key metrics regarding the amended loan include:

  • Interest Rate: Three-month LIBOR (minimum 2.00%) plus an applicable margin.
  • Margin Tiers:
    • 10.00% standard margin.
    • 9.00% if leverage ratio is less than 4.00:1.
    • 7.00% if leverage ratio is less than 3.00:1.
  • Amortization: The first amortization date was extended to May 14, 2020, allowing for interest-only payments for the next four quarterly periods.
  • Additional Liquidity: Up to $5,000,000 in additional principal is available subject to revenue and market capitalization conditions.

The filing text does not provide current values for total revenue, profit, cash flow, or existing debt principal balances.

Material Changes Versus Prior Period

Compared to the original July 19, 2017 agreement, the Amendment introduces the following changes:

  • Implementation of a variable interest rate margin based on leverage ratios.
  • Extension of the interest-only period through May 2020.
  • Inclusion of recently created subsidiaries as co-borrowers.
  • Addition of definitions for "excluded subsidiaries" intended for future deconsolidation.

Outlook, Risks, and Contingencies

Management's ability to access the additional $5,000,000 credit facility is contingent upon meeting specific revenue and market capitalization requirements. The leverage ratio calculation includes specific add-backs for litigation expenses, indicating ongoing legal contingencies that impact financial covenants. The Company is not classified as an emerging growth company in this filing.

Investor Verification Checklist

  • Verify the Company's current leverage ratio to determine the applicable interest rate margin (7%, 9%, or 10%).
  • Confirm whether the revenue and market capitalization conditions for the $5,000,000 additional drawdown have been met.
  • Review the full text of Exhibit 10.1 for specific definitions of "excluded subsidiaries" and potential deconsolidation impacts.
  • Assess the impact of the litigation expense add-backs on the Company's reported EBITDA and covenant compliance.

News